Single-antibody, targeted nanoparticle delivery of camptothecin. - Wikidata - thesis-toulmin - TriplyDB

Single-antibody, targeted nanoparticle delivery of camptothecin.

Single-antibody, targeted nanoparticle delivery of camptothecin.

http://www.wikidata.org/entity/Q37227392

about

Nanocarrier for poorly water-soluble anticancer drugs--barriers of translation and solutions.Theranostic nanoparticles carrying doxorubicin attenuate targeting ligand specific antibody responses following systemic delivery.Exploring silver as a contrast agent for contrast-enhanced dual-energy X-ray breast imaging.Well-defined single polymer nanoparticles for the antibody-targeted delivery of chemotherapeutic agents.Targeted nanoparticles assembled via complexation of boronic-acid-containing targeting moieties to diol-containing polymers.Antibody targeting facilitates effective intratumoral siRNA nanoparticle delivery to HER2-overexpressing cancer cells CD44v6-Peptide Functionalized Nanoparticles Selectively Bind to Metastatic Cancer Cells.Antibody-targeted biodegradable nanoparticles for cancer therapy.Camptothecin-based nanodrug delivery systems.A polymeric temozolomide nanocomposite against orthotopic glioblastoma xenograft: tumor-specific homing directed by nestin.

P2860

Q33962553-4E1CF533-C23A-40B1-A928-22C5E828F36B Q34698633-6B5A304A-9D21-4782-A108-C97076A9BC70 Q35676703-D14EC036-D714-408C-8900-72ADECE845B7 Q35751371-68F9056F-E055-43C6-8935-442F835DED93 Q36850978-32050A86-29A5-432F-9692-4A19F97D211E Q36962681-C7D9CC65-6D4E-4E41-8260-29C88302573E Q37588008-0F43B768-1A1D-49A1-AFDF-344C875C938E Q38665261-59AB2295-9BDC-4D2C-BFF1-8E58624D82AE Q47700115-5ECCAD70-4537-43A4-A2D3-190F8B43E362 Q48185664-80146FB1-D001-4036-814A-21161BE9297E

P2860

Single-antibody, targeted nanoparticle delivery of camptothecin.

http://www.wikidata.org/entity/Q37227392

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 29 May 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Single-antibody, targeted nanoparticle delivery of camptothecin.

@en

Single-antibody, targeted nanoparticle delivery of camptothecin.

@nl

type

label

Single-antibody, targeted nanoparticle delivery of camptothecin.

@en

Single-antibody, targeted nanoparticle delivery of camptothecin.

@nl

prefLabel

Single-antibody, targeted nanoparticle delivery of camptothecin.

@en

Single-antibody, targeted nanoparticle delivery of camptothecin.

@nl

P1433

Q37227392-6402B6EB-65C4-477A-8DD7-E5529FB30D97

P1476

Q37227392-637AEA1B-856B-4E44-A212-92D312A5E49D

P2093

Q37227392-3A44B26C-EF78-4BA6-BD54-918F8DF06EEA

Q37227392-97CDD46B-9742-4B46-9767-604EC8B204EB

P2860

Q37227392-04817425-5CC6-4101-902A-50A5EADB9EA9

Q37227392-08E34165-B2E3-4323-A91D-A9E7EA407A7A

Q37227392-0CD85523-33D2-45AD-8141-ACDF7302752D

Q37227392-13105D42-AADA-45E1-97E9-8C4A23D58DFE

Q37227392-1BFF2042-52AE-4667-8AAF-05F37E8A9A52

Q37227392-209DF934-0CA9-4EB8-955F-9A1C308E8933

Q37227392-306B2163-4746-4E54-9CCB-ACE5C0F1BB69

Q37227392-3490CCF8-C685-40DD-A6EF-DB4066D7D018

Q37227392-35CC846F-B565-4DDC-ABCA-FDBD612835A1

Q37227392-39E18810-5793-4A9F-AF60-6EA27913E441

P304

Q37227392-05EA726B-FEC6-496D-BCFD-0B0753D6482D

P31

Q37227392-20D77C66-862C-47DC-8534-A1721ACFD95D

P356

Q37227392-6AD143B8-E923-4D6F-8759-2783A20369E5

P407

Q37227392-97E0008B-77D9-4A09-A9FD-F59F06E69E4F

P433

Q37227392-217AFA8B-94FA-4DE5-8E04-3DBBB0348DDD

P478

Q37227392-5B632870-5D19-431D-98B8-09F5633CB14F

P577

Q37227392-C10541B2-01C4-4F30-8C0D-2B47949E67A1

P698

Q37227392-A4BB0224-48D7-47C6-8364-6BA8703D85C2

P921

Q37227392-11120036-BB8E-4297-870F-C5FA844EB69E

Q37227392-3F89EEE5-DBBF-43A2-AB91-69F21B216EE4

Q37227392-521F32F2-14D1-49CA-AF85-83BBCBE47F3D

P932

Q37227392-C1108C4F-2462-4150-B32D-23B7DC9BE8AC

P356

P1433

Molecular Pharmaceutics

P1476

Single-antibody, targeted nanoparticle delivery of camptothecin.

@en

P2093

Han Han

http://www.w3.org/2001/XMLSchema#string

Mark E Davis

http://www.w3.org/2001/XMLSchema#string

P2860

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Trastuzumab emtansine for HER2-positive advanced breast cancer.

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies

Antibody therapy of cancer

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).

A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma.

P304

2558-2567

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/MP300702X

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23676007

http://www.w3.org/2001/XMLSchema#string

P921

P932

3795804

http://www.w3.org/2001/XMLSchema#string